Shares of Clovis Oncology Inc. (NASDAQ:CLVS) have received a consensus recommendation of “Buy” from the twelve analysts that are currently covering the company. Six research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $38.06.
CLVS has been the topic of several recent analyst reports. SunTrust Banks Inc. upped their price objective on shares of Clovis Oncology from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, September 23rd. Piper Jaffray Cos. reissued a “neutral” rating and set a $42.00 price objective on shares of Clovis Oncology in a research note on Wednesday, October 12th. Zacks Investment Research downgraded shares of Clovis Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, October 4th. Credit Suisse Group AG reissued an “outperform” rating and set a $41.00 price objective on shares of Clovis Oncology in a research note on Monday, October 10th. Finally, Janney Montgomery Scott downgraded shares of Clovis Oncology from a “buy” rating to a “neutral” rating and upped their price objective for the company from $35.00 to $36.00 in a research note on Wednesday, September 21st.
Shares of Clovis Oncology (NASDAQ:CLVS) opened at 31.85 on Thursday. Clovis Oncology has a 52-week low of $11.57 and a 52-week high of $109.18. The stock’s 50 day moving average is $31.36 and its 200 day moving average is $19.25. The stock’s market capitalization is $1.23 billion.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.13) by $0.06. During the same quarter in the previous year, the company posted ($2.10) EPS. Equities research analysts expect that Clovis Oncology will post ($9.25) earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in CLVS. Alps Advisors Inc. raised its stake in Clovis Oncology by 25.1% in the second quarter. Alps Advisors Inc. now owns 53,924 shares of the biopharmaceutical company’s stock worth $740,000 after buying an additional 10,828 shares during the last quarter. Candriam Luxembourg S.C.A. raised its stake in Clovis Oncology by 46.9% in the second quarter. Candriam Luxembourg S.C.A. now owns 47,000 shares of the biopharmaceutical company’s stock worth $645,000 after buying an additional 15,000 shares during the last quarter. Old Mutual Global Investors UK Ltd. purchased a new stake in Clovis Oncology during the second quarter worth $1,234,000. Fox Run Management L.L.C. purchased a new stake in Clovis Oncology during the second quarter worth $154,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in Clovis Oncology during the first quarter worth $233,000. 98.50% of the stock is owned by institutional investors.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.